SciELO - Scientific Electronic Library Online

vol.26 número1Efectos del tratamiento multimodal en pacientes con síndrome de dolor regional complejo tipo 1 con, al menos, seis meses de evolución: un estudio descriptivoFactores psicosociales en el dolor crónico oncológico: un estudio Delphi índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Revista de la Sociedad Española del Dolor

versão impressa ISSN 1134-8046


GUILLEN-RAMIREZ, N. et al. Dexmedetomidine versus endovenous lidocaine in breakthrough pain control and functionality in patients with lumbar stenosis. Rev. Soc. Esp. Dolor [online]. 2019, vol.26, n.1, pp.14-20. ISSN 1134-8046.


The pain is a reason for absenteeism labour, especially breakthrough pain secondary to narrow lumbar canal. Dexmedetomidine is an analgesic, act by inhibiting the release of substance P in the nociceptive pathway and blocks the aspartate and glutamate receptors. On the other hand, lidocaine also prevents and relieves pain by interrupting neuroconduction, binding to its specific receptor within the sodium channels.


To evaluate the analgesic efficacy of dexmedetomidine versus lidocaine in intravenous perfusion as a treatment for breakthrough pain secondary to narrow lumbar canal.

Material and methods:

Controlled clinical trial, randomized, triple-blind, performed at the HGM pain clinic, two groups of patients with diagnosis of breakthrough pain secondary to narrow lumbar canal were evaluated; group one was treated with dexmedetomidine (0.3 mcg/kg) and the other group was treated with lidocaine (2 mg/kg) in intravenous infusion. Measurement of pain intensity and sedation status was made before starting the treatment and after 30, 60 and 120 minutes. The functionality of the patients was also assessed through the Oswestry disability index before and seven days after treatment. Secondarily evaluated the effect of treatments on vital signs.


There was not any statistically significant difference in the reduction of pain intensity at 120 minutes between patients treated with dexmedetomidine (EVA 1.29 ± 1.63) compared with those who were treated with lidocaine (EVA 1 ± 1.19, p = 0.594), it was observed that at the end of drugs perfusion, dexmedetomidine produced greater sedation, unlike lidocaine (p = 0.003), both treatments improved functionality in all patients without having a statistically significant difference between treatments (p = 0.508), they were not observed depressant effects on vital signs.


Dexmedetomidine and lidocaine are just as equally effective for the treatment of breakthrough pain, with onset of action in the first 30 minutes after the infusion started until the next 2 hours, no adverse drug events were observed at the recommended doses.

Palavras-chave : Breakthrough pain; dexmedetomidine; lidocaine; narrow lumbar canal.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )